Almoosa Health Company (4018) Fair Value & Analysis
Healthcare · SA · Market cap 5.1B SAR
Fair value as of: Jul 31, 2026
From 16 valuation models · updated today
Share price −2.5% over the past month.
What matters now
- The price sits above even our optimistic bull case (96.12 SAR). The favourable scenario is already priced in.
- Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (12 months)
12‑month range 111.20 SAR – 198.68 SAR · fair‑value band 57.67 SAR – 96.12 SAR · the 116.00 SAR price screens above the 76.90 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Almoosa Health Company (4018) currently trades at 116.00 SAR, while our model-based Fair Value estimate is 76.90 SAR, implying the stock looks roughly 33.7% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Almoosa Health Company generated revenue of 1.4B SAR at a net margin of 13.4%. Revenue grew 7.8% year over year. It earns a return on equity of 10.0%. Net debt stands at 769M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 57.67 SAR (bear case) to 96.12 SAR (bull case); at 116.00 SAR, the current price sits above that range. The share trades about 45% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -19% fair-value upside, at -34%, 4018 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Almoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items.
Full company description
Almoosa Health Company operates as a private healthcare provider in the Kingdom of Saudi Arabia. It stores medical items and sells medicine, cosmetics, and disposable medical items. The company also operates specialist and rehabilitation hospitals, medical and emergency centers, pharmacies, mental health clinics, and oncology centers, as well as a college of health sciences. Its medical specialties include pain management, lymphatic massage, hyperbaric oxygen therapy, occupational therapy, speech and language disorders, personality and behavioral disorders, supportive devices and prosthetics, urology, ophthalmic surgery, general surgery, otolaryngology (ear, nose, and throat), wound care, emergency medicine, audiology, rheumatology, allergy and immunology, health education, angiography and interventional radiology, infectious diseases, chest diseases, dermatology, internal medicine, pediatrics, dentistry, nephrology, endocrinology, gastroenterology, pediatric neurology, physiotherapy, psychiatry, bone and joint surgery, psychiatric rehabilitation, therapeutic nutrition, and vascular medicine. The company was formerly known as Al Moosa Specialist Hospital and changed its name to Almoosa Health Company in February 2024. The company was incorporated in 1996 and is based in Al Mubarraz, the Kingdom of Saudi Arabia. Almoosa Health Company operates as a subsidiary of Abdulaziz bin Abdullah Almoosa Investment Company.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Almoosa Health Company reported revenue of 1.4B SAR in FY2025 versus 702M SAR in FY2021, a compound +19.2%/yr. Reported net income was 200M SAR in FY2025, compounding +33.9%/yr from FY2021.
Is 4018 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$100.00 | R$25.67 | -74% |
| Fresenius SE FRE | €39.54 | €31.98 | -19% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| DaVita Inc DVAI34 | R$1,002 | R$1,038 | +4% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,305 | ₹2,546 | -69% |
| Fresenius Medical Care AG FMSC34 | R$112.00 | R$164.60 | +47% |
| Aier Eye Hospital Group 300015 | ¥8.54 | ¥6.73 | -21% |
Compare Almoosa Health Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Almoosa Health Company (4018) overvalued or undervalued?
What is the fair value of 4018?
What is the quality score of 4018?
What is the revenue of Almoosa Health Company (4018)?
What is the net profit margin of 4018?
Does Almoosa Health Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Almoosa Health Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.